{
    "Trade/Device Name(s)": [
        "Etest\u00ae Ceftolozane / Tazobactam"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K170670",
    "Predicate Device Reference 510(k) Number(s)": [
        "K151873"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JWY"
    ],
    "Summary Letter Date": "May 31, 2017",
    "Summary Letter Received Date": "March 6, 2017",
    "Submission Date": "March 3, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.1640"
    ],
    "Regulation Name(s)": [
        "Antimicrobial susceptibility test powder"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ceftolozane/Tazobactam susceptibility",
        "Minimum Inhibitory Concentration (MIC)"
    ],
    "Specimen Type(s)": [
        "Clinical isolate (bacteria)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Gradient diffusion",
        "Agar-based MIC determination"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing"
    ],
    "Submission Type(s)": [
        "Test",
        "Reagent",
        "Strip test"
    ],
    "Document Summary": "FDA 510(k) summary for Etest\u00ae Ceftolozane / Tazobactam antimicrobial susceptibility strip for determining MIC against Gram negative aerobic bacteria",
    "Indications for Use Summary": "Quantitative determination of antimicrobial susceptibility for Gram negative and Gram positive aerobic and fastidious bacteria using a predefined antibiotic gradient to determine MIC on agar media after overnight incubation",
    "fda_folder": "Microbiology"
}